Back to Search
Start Over
Albumin-bound paclitaxel plus gemcitabine after first-line FOLFIRINOX therapy in patients with pancreatic cancer
- Source :
- Journal of Clinical Oncology. 32:e15252-e15252
- Publication Year :
- 2014
- Publisher :
- American Society of Clinical Oncology (ASCO), 2014.
-
Abstract
- e15252 Background: Albumin-bound paclitaxel plus gemcitabine (Gem/nab) and FOLFIRINOX are approved as first-line therapies for metastatic pancreatic cancer (PC). Optimal regimen sequence is unknown...
- Subjects :
- Oncology
Cancer Research
medicine.medical_specialty
endocrine system diseases
business.industry
FOLFIRINOX
First line
medicine.disease
Gemcitabine
Regimen
chemistry.chemical_compound
Albumin bound paclitaxel
Paclitaxel
chemistry
Internal medicine
Pancreatic cancer
medicine
In patient
business
medicine.drug
Subjects
Details
- ISSN :
- 15277755 and 0732183X
- Volume :
- 32
- Database :
- OpenAIRE
- Journal :
- Journal of Clinical Oncology
- Accession number :
- edsair.doi...........0f1c70f28505cef988bd73488e287c80
- Full Text :
- https://doi.org/10.1200/jco.2014.32.15_suppl.e15252